Cargando…
Extending the chimeric receptor-based T-cell targeting strategy to solid tumors
The adoptive transfer of T cells expressing chimeric antigen receptors (CARs) has emerged as a promising immunotherapeutic strategy against cancer. Administering CAR-expressing T cells in combination with agents that promote the expression of CAR targets or optimize T-cell function within the tumor...
Autor principal: | Rossig, Claudia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3825720/ https://www.ncbi.nlm.nih.gov/pubmed/24244901 http://dx.doi.org/10.4161/onci.26091 |
Ejemplares similares
-
Immune modulation by molecular cancer targets and targeted therapies: Rationale for novel combination strategies
por: Rossig, Claudia
Publicado: (2012) -
A new strategy to target regulatory T cells in solid tumors
por: Thomas-Schoemann, Audrey, et al.
Publicado: (2013) -
CD123 AML targeting by chimeric antigen receptors: A novel magic bullet for AML therapeutics?
por: Tettamanti, Sarah, et al.
Publicado: (2014) -
Engineered chimeric antigen receptor-expressing T cells for the treatment of pancreatic ductal adenocarcinoma
por: Beatty, Gregory L
Publicado: (2014) -
Lessons learned from a highly-active CD22-specific chimeric antigen receptor
por: Long, Adrienne H., et al.
Publicado: (2013)